ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics – Xconomy
Xconomy |
ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics
Xconomy In a deal that consolidates its position as a leader in developing a stem cell-derived treatment for diabetes, San Diego's ViaCyte says today it is absorbing its chief rival, New Jersey-based Janssen BetaLogics. The asset deal comes in conjunction with … ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell … Johnson & Johnson, ViaCyte Testing Possible Diabetes Cure Possible diabetes cure being tested on small number of patients |
